Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 10,000 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 8th. The stock was sold at an average price of $70.18, for a total transaction of $701,800.00. Following the transaction, the insider now directly owns 523,904 shares of the company’s stock, valued at approximately $36,767,582.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Derek J. Maetzold also recently made the following trade(s):

  • On Monday, April 26th, Derek J. Maetzold sold 14,374 shares of Castle Biosciences stock. The stock was sold at an average price of $69.17, for a total transaction of $994,249.58.

NASDAQ:CSTL opened at $71.22 on Friday. The stock’s 50-day moving average is $63.70. Castle Biosciences, Inc. has a 52-week low of $34.72 and a 52-week high of $107.69. The company has a market cap of $1.78 billion, a P/E ratio of -100.31 and a beta of 0.42.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Sunday, May 9th. The company reported ($0.17) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $22.81 million for the quarter, compared to analysts’ expectations of $16.66 million. Castle Biosciences had a negative net margin of 22.24% and a negative return on equity of 4.74%. The firm’s revenue for the quarter was up 30.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.03 earnings per share. As a group, research analysts forecast that Castle Biosciences, Inc. will post -0.92 earnings per share for the current fiscal year.

Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Monday, May 10th. Robert W. Baird restated a “buy” rating and set a $73.00 price objective on shares of Castle Biosciences in a report on Thursday, May 13th. Finally, Lake Street Capital assumed coverage on shares of Castle Biosciences in a report on Friday, April 30th. They set a “buy” rating and a $94.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Castle Biosciences has an average rating of “Buy” and a consensus target price of $80.29.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC increased its stake in Castle Biosciences by 25.6% in the first quarter. ARK Investment Management LLC now owns 2,597,288 shares of the company’s stock valued at $177,810,000 after acquiring an additional 528,696 shares during the period. Wasatch Advisors Inc. increased its stake in Castle Biosciences by 14.0% in the first quarter. Wasatch Advisors Inc. now owns 2,353,479 shares of the company’s stock valued at $161,119,000 after acquiring an additional 288,648 shares during the period. BlackRock Inc. increased its stake in Castle Biosciences by 19.5% in the first quarter. BlackRock Inc. now owns 1,363,836 shares of the company’s stock valued at $93,369,000 after acquiring an additional 222,089 shares during the period. Pembroke Management LTD increased its stake in Castle Biosciences by 77.2% in the first quarter. Pembroke Management LTD now owns 461,222 shares of the company’s stock valued at $31,575,000 after acquiring an additional 200,976 shares during the period. Finally, GW&K Investment Management LLC increased its stake in Castle Biosciences by 353.2% in the fourth quarter. GW&K Investment Management LLC now owns 452,391 shares of the company’s stock valued at $30,378,000 after acquiring an additional 352,568 shares during the period. 84.99% of the stock is currently owned by institutional investors and hedge funds.

About Castle Biosciences

Castle Biosciences, Inc, a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue.

Recommended Story: What causes a recession?

Insider Buying and Selling by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.